Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Peter H O'DonnellHendrick Tobias ArkenauSrikala S SridharMichael OngAlexandra DrakakiAlexander I SpiraJingsong ZhangMichael S GordonArnold N DegboeAshok K GuptaPralay MukhopadhyayWenmei HuangShaad E AbdullahNatasha AngraLorin K RoskosXiang GuoTerence FriedlanderPublished in: Cancer (2019)
Durvalumab was associated with improvements in disease-related symptoms, functioning, and HRQOL in patients with mUC. Improvements in systemic inflammation may contribute to PRO improvements in these patients.
Keyphrases
- patient reported outcomes
- squamous cell carcinoma
- end stage renal disease
- locally advanced
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- neoadjuvant chemotherapy
- radiation therapy
- peritoneal dialysis
- randomized controlled trial
- depressive symptoms
- anti inflammatory
- patient reported